The new patent has a scheduled expiry date in 2028, not including any potential regulatory extensions.
The HuCAL-derived, fully human antibody is currently being tested in a Phase I/IIa trial in patients with relapsed/refractory myeloma.
MorphoSys chief scientific officer Marlies Sproll said that in 2011, MOR202 became their third proprietary antibody program in clinical trials, following MOR103 in and MOR208.
"Strengthening our intellectual property position on our proprietary products, particularly in our most important markets Europe, the USA and Asia, is of high priority for MorphoSys," Sproll added.